Cardiovascular Systems to distribute Invatec balloon catheter

Invatec, a provider of interventional products, has entered into a distribution agreement with interventional vascular disease treatment system developer Cardiovascular Systems, which recently merged with the biotech firm Replidyne.

Under the terms of the agreement, the St. Paul, Minn.-based CSI will distribute Invatec's recently FDA-cleared percutaneous transluminal angioplasty (PTA) balloon catheter product line, according to the Bethlehem, Pa.-based Invatec. The CSI and Invatec sales forces will partner in selling the Amphirion Deep 0.014 inch PTA balloon catheter line, a below the knee PTA catheter, as well as the Submarine Plus 0.018-inch PTA balloon catheter and the Admiral Xtreme 0.035-inch PTA balloon catheter lines.

Invatec said it will continue to sell and market its other interventional products, such as its thrombus management cathether, the Diver CE and the FiberNet Embolic Protection system.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."